ライフサイエンスコーパス: serous

1 ith better survival (p = 0.01) in high-grade serous.

2 varied by histotype, with increased risk of serous [1.13 (1.09-1.17)], endometrioid [1.20 (1.10-1.32

3 15] with adjustment for LOC components [1.08 serous, 1.11 endometrioid, 1.26 clear cell, 0.94 mucinou

4 ed invasive epithelial ovarian cancer (2,045 serous, 319 endometrioid, 184 mucinous, 121 clear cell,

5 elial ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell,

6 derived from malignant ascites of high-grade serous adenocarcinoma patients.

7 d 3), whereas for type 2 endometrial cancer (serous and carcinosarcoma), UBC, MRPL19, PGK1 and PPIA w

8 stological subtypes, including endometrioid, serous and clear cell carcinomas.

9 hat they occurred more commonly in eyes with serous and drusenoid PED.

10 low-grade serous carcinomas from high-grade serous and mucinous carcinomas.

11 lts highlight mutational differences between serous and non-serous ovarian cancers, and further disti

12 Five serous and/or serous-like (serous/serous-like) endometri

13 ith both nonvascularized PEDs (drusenoid and serous) and vascularized PEDs (type 1 and type 3 neovasc

14 expression of IRF6 in the developing ductal, serous, and mucous acinar cells of salivary glands.

15 Dissimilarly, serous borderline ovarian tumors (BOT) can progress into

16 visualization of fine papillary branches in serous BOT and allowed for characterization of spatial f

17 ssive endometrial cancers, including uterine serous cancer and uterine carcinosarcoma, which together

18 at miR-200b had an overall elevated level in serous cancer compared with controls, whereas miR-429 wa

19 Ovarian and uterine serous cancers are extremely lethal diseases that often

20 nded, especially for women with stage III or serous cancers, or both, as part of shared decision maki

21 emonstrate challenges for risk prediction of serous cancers, the most fatal subtype.

22 molecular aberration in the FTE occurring in serous carcinogenesis followed by a mutation in p53.

23 r cell carcinoma (Arid1a, Pik3ca), low-grade serous carcinoma (Braf), endometrioid (Ctnnb1), or mucin

24 ust preclinical models of ovarian high-grade serous carcinoma (HGSC) are needed to advance our unders

25 g evidence indicates that ovarian high-grade serous carcinoma (HGSC) originates from fallopian tube s

26 lantable murine models of ovarian high grade serous carcinoma (HGSC) remain an important research too

27 Ovarian high-grade serous carcinoma (HGSC) results in the highest mortality

28 Tumors of the high-grade serous carcinoma (HGSC) type represent the most common f

29 lantable murine models of ovarian high-grade serous carcinoma (HGSC) with regard to mutations in the

30 High-grade serous carcinoma (HGSC), an epithelial cancer phenotype,

31 ailing paradigm in the genesis of high-grade serous carcinoma (HGSC), the most common ovarian cancer,

32 cantly increased risk for ovarian high-grade serous carcinoma (HGSC; 3.8% cases vs. 0.2% controls).

33 g squamous cell carcinoma (LSCC) and ovarian serous carcinoma (OSC).

34 r axis changes in a mouse model of oviductal serous carcinoma closely mirror those of human tubo-ovar

35 High-grade serous carcinoma has a poor prognosis, owing primarily t

36 onvertase, is highly expressed in high-grade serous carcinoma of ovarian cancer patients, and its exp

37 Final pathology confirmed high-grade serous carcinoma of ovarian origin ( Fig 1B ) that was d

38 erapy in women with stage II to IV low-grade serous carcinoma of the ovary or peritoneum.

39 a deep analysis of one patient with advanced serous carcinoma of the ovary.

40 ation of chemotherapy in ovarian and uterine serous carcinoma patients by biodegradable nanoparticles

41 -terminal CXCL16 was significantly higher in serous carcinoma tissues compared to endometrioid.

42 nclusion Women with stage II to IV low-grade serous carcinoma who received HMT after primary treatmen

43 High-grade serous carcinoma, accounts for up to 70% of all ovarian

44 common subtype of ovarian cancer, high-grade serous carcinoma, has sparked a major effort within the

45 Uterine serous carcinoma, one of the most aggressive types of en

46 against i.p. chemotherapy-resistant uterine serous carcinoma-derived xenografts compared with free E

47 rotransposition events in high-grade ovarian serous carcinoma.

48 irror those of human tubo-ovarian high-grade serous carcinoma.

49 al fallopian tube among all cases.High-grade serous carcinomas (HGSCs) are associated with precursor

50 Many high-grade serous carcinomas (HGSCs) likely originate in the distal

51 Many high-grade serous carcinomas (HGSCs) of the pelvis are thought to o

52 e Atlas (TCGA), of which 169 were high-grade serous carcinomas (HGSCs).

53 ian tumors (BOT) can progress into low-grade serous carcinomas and have relatively indolent clinical

54 en observed at high frequency in endometrial serous carcinomas but at low frequency in ovarian clear

55 However not all cell lines derived from non-serous carcinomas exhibited similar invasive behaviour.

56 ated endometrioid, clear cell, and low-grade serous carcinomas from high-grade serous and mucinous ca

57 Cell lines derived from non-serous carcinomas migrated more quickly and were more li

58 e composed, for the most part, of high-grade serous carcinomas that can be further subdivided into mo

59 ll lines were derived, given that high-grade serous carcinomas typically expand and spread over perit

60 ates than cell lines derived from high-grade serous carcinomas.

61 , and seromucinous carcinomas; ii) low-grade serous carcinomas; and iii) mucinous carcinomas and mali

62 d innate-like B-cell immune responses in the serous cavities.

63 atelike lymphocytes that primarily reside in serous cavities.

64 We recently found that serous-cavity TRMs (LPMs) are highly enriched in RXR tra

65 in a subset of mononuclear leukocytes and in serous cells of submucosal glands.

66 Chronic central serous chorioretinopathy (cCSC) is a chorioretinal disea

67 fe (VRQOL) between acute and chronic Central serous chorioretinopathy (CSC) and correlate this with C

68 a rare and severe variant of chronic central serous chorioretinopathy (CSC).

69 Central serous chorioretinopathy (CSCR) is a complex ocular enti

70 Central serous chorioretinopathy (CSCR) is a rare side-effect no

71 In chronic central serous chorioretinopathy (CSCR), fluid accumulates in th

72 ith choroidal neovascularization and central serous chorioretinopathy (CSCR).

73 49.6 years SD +/- 10.5) with chronic central serous chorioretinopathy (mean duration 18.9 months SD +

74 ent after long-standing but resolved central serous chorioretinopathy and refer it to healthy individ

75 to a fifth of patients with chronic central serous chorioretinopathy but carry a relatively good vis

76 three eyes of 30 patients with acute central serous chorioretinopathy comprised the comparative group

77 Chronic central serous chorioretinopathy is a potentially damaging clini

78 orrected visual acuity after chronic central serous chorioretinopathy was 0.23 logMAR (0.6 Snellen) a

79 Consecutive patients with chronic central serous chorioretinopathy were identified from the clinic

80 Sixty-seven patients with chronic central serous chorioretinopathy were identified.

81 utive cohort of patients, with acute central serous chorioretinopathy, was also examined for the pres

82 e distinguished from the findings of central serous chorioretinopathy.

83 st that they are specific to chronic central serous chorioretinopathy.

84 l lymphoma, myopic degeneration, and central serous chorioretinopathy.

85 age-related macular degeneration or central serous chorioretinopathy.

86 tetrics (FIGO; 1988) stage IC-IIA high-grade serous, clear cell, or any poorly differentiated or grad

87 ors and compared our results to TCGA ovarian serous cystadenocarcinoma and uterine corpus endometrial

88 project: glioblastoma multiforme and ovarian serous cystadenocarcinoma.

89 patients with IPMN, but not in patients with serous cystadenoma or controls.

90 should be distinguished from serous lesions (serous cystadenomas) that are nearly always benign.

91 Although many cysts, such as pseudocysts and serous cystadenomas, are benign and can be monitored cli

92 cinous neoplasms, mucinous cystic neoplasms, serous cystadenomas, solid pseudopapillary neoplasms, cy

93 fluid and pre-operative plasma from IPMN and serous cystic neoplasm (SCN) patients in a pancreas rese

94 Our aim is to provide a real-life picture of serous cystic neoplasms (SCNs) management once a presump

95 f vision, presence of subretinal hemorrhage, serous detachment, retinal pigment epithelial detachment

96 eye revealed macular retinoschisis, without serous detachment.

97 tures of AEPVM, including initial localized, serous detachments followed by the development of charac

98 ignaling, illuminating the genetic basis for serous EC development and its potential control by ratio

99 genomic alterations that occur frequently in serous endometrial carcinoma (EC) and carcinosarcoma, tw

100 e compared as were the carcinoma histotypes (serous, endometrioid, clear cell).

101 years and older with stage III/IV high-grade serous, endometrioid, or clear cell ovarian cancer in cl

102 y loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33,

103 Kras(G12D)-mutant mouse strain that develops serous EOC with 100% penetrance to introduce the mutant

104 eptibility gene for low-grade and borderline serous EOC.

105 tations in non-serous was much lower than in serous epithelial OC, whereas the prevalence of PIK3CA,

106 dies have revealed the mutation landscape of serous epithelial ovarian cancer, other non-serous subty

107 Here we conduct exome sequencing of nine non-serous epithelial ovarian tumors (six endometrioid and t

108 rs and FLAgs, thus combining the mucosal and serous exit of mobile leukocytes and increasing the rang

109 te a 30-40-fold increased risk of high-grade serous extra-uterine Mullerian cancers (HGSEMC), otherwi

110 ients (>=18 years) with relapsed, high-grade serous (grade 2 or 3) epithelial ovarian, fallopian tube

111 High-grade serous (HGS) ovarian cancer accounts for 90% of all ovar

112 , or primary peritoneal cancer of high-grade serous histology; confirmed diagnosis of either recurren

113 We aim to understand how serous (i.e., basement membrane) versus fibrous (i.e., n

114 t potential and should be distinguished from serous lesions (serous cystadenomas) that are nearly alw

115 Five serous and/or serous-like (serous/serous-like) endometrial carcinomas

116 e agents have been associated with a central serous-like retinopathy in some patients.

117 R signalling controls the maintenance of the serous macrophage pool and that targeting peritoneal LPM

118 Here, we show that RXRs control mouse serous-macrophage identity by regulating chromatin acces

119 common ovarian cancer histotypes (low grade serous, mucinous, and clear cell carcinomas), the inabil

120 year, the therapy was started again and the serous neuroretinal detachment appeared once more, howev

121 Fundoscopy showed serous neuroretinal detachment of the fovea accompanied

122 ify 13 candidate causal SNPs associated with serous OC (P=9.2 x 10(-20)), ER-negative BC (P=1.1 x 10(

123 or III disease; or stage I-III disease with serous or clear cell histology; were aged 18 years and o

124 tumors, ORlog2 = 1.40 (1.03-1.91)], but not serous or clear cell.

125 platinum-based chemotherapy with high-grade serous or endometrioid EOC should be offered PARPi maint

126 older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or f

127 older who had platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or f

128 lder with measurable or evaluable high-grade serous or endometrioid platinum-sensitive recurrent ovar

129 loiting the sidedness of BP scaffolds (i.e., serous or fibrous surface), this study aims to determine

130 although not statistically significant, for serous (OR = 1.43; 95% CI = 0.82-2.49) and clear cell ca

131 sorder, receptive language disorder, chronic serous otitis media, and expressive language disorder.

132 ith recurrent, platinum-resistant high-grade serous ovarian cancer (determined histologically) and Ea

133 BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are associated with favorab

134 High-grade serous ovarian cancer (HGSC) is an aggressive cancer wit

135 of the progenitor populations for high-grade serous ovarian cancer (HGSC).

136 recognized as a site of origin of high-grade serous ovarian cancer (HGSC).

137 mor tissue from 158 patients with high-grade serous ovarian cancer (HGSOC) and 100 control patients w

138 y develops in women with advanced high-grade serous ovarian cancer (HGSOC) and is associated with dru

139 ted tomography (CT) phenotypes of high-grade serous ovarian cancer (HGSOC) and to evaluate CT indicat

140 identify susceptibility genes for high-grade serous ovarian cancer (HGSOC) by performing a transcript

141 t are differentially expressed in high-grade serous ovarian cancer (HGSOC) cell lines compared with n

142 High grade serous ovarian cancer (HGSOC) is a fatal gynecologic mal

143 High grade serous ovarian cancer (HGSOC) is the fifth leading cause

144 rging evidence has indicated that high-grade serous ovarian cancer (HGSOC) originates in the fallopia

145 repressed in approximately 30% of high-grade serous ovarian cancer (HGSOC) patients and is a recurren

146 l study of advanced and recurrent high-grade serous ovarian cancer (HGSOC) patients in which we asses

147 cell line representative of human high-grade serous ovarian cancer (HGSOC) should not only resemble i

148 ration to predict the response of high grade serous ovarian cancer (HGSOC) to neoadjuvant chemotherap

149 mography (CT) imaging features of high-grade serous ovarian cancer (HGSOC), to assess their associati

150 eoadjuvant chemotherapy (NACT) in high-grade serous ovarian cancer (HGSOC), we performed immunogenomi

151 proved biomarkers for olaparib in high-grade serous ovarian cancer (HGSOC).

152 oups, especially in patients with high-grade serous ovarian cancer (HGSOC).

153 ge for the clinical management of high grade serous ovarian cancer (HGSOC).

154 use of morbidity and mortality in high-grade serous ovarian cancer (HGSOC).

155 lity (h(g)(2)) of EOC overall and high-grade serous ovarian cancer (HGSOCs) were estimated to be 5%-6

156 uded 244 patients with pathologically proven serous ovarian cancer (mean age +/- standard deviation,

157 In high-grade serous ovarian cancer (OV), the bulk of genetic changes

158 Here we show that NGH in serous ovarian cancer (SOC) can be accurately measured w

159 r microenvironment composition in high-grade serous ovarian cancer and follicular lymphoma.

160 cedes the radiologic detection of high-grade serous ovarian cancer by at least 2 mo and the final cli

161 er patient-derived xenografts and high-grade serous ovarian cancer cell lines and discover clone-spec

162 In the serous ovarian cancer cells (IGROV and OVCAR-3), shPKCio

163 onally silenced, HR+, CARM1-high, high-grade serous ovarian cancer cells become PARPi sensitive, unde

164 PR)-mediated knockout of FABP4 in high-grade serous ovarian cancer cells reduced metastatic tumor bur

165 est DESI-MS as a powerful approach for rapid serous ovarian cancer diagnosis based on altered metabol

166 High-grade serous ovarian cancer is the most common ovarian cancer

167 stologically confirmed, relapsed, high-grade serous ovarian cancer or high-grade endometrioid cancer,

168 High-grade serous ovarian cancer patient tumors and cells express s

169 In matched samples from 11 high-grade serous ovarian cancer patients, we detected 2-20-fold mo

170 metastases, and ascites cells isolated from serous ovarian cancer patients.

171 th BRCA-mutated platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance mon

172 We performed an analysis of CNV data of 587 serous ovarian cancer samples on multiple platforms.

173 line and as small as 9 Mb in two high-grade serous ovarian cancer samples using only 0.02x depth.

174 ratin in 220 tissue cores from 26 high-grade serous ovarian cancer samples.

175 Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end

176 d multi-omics profiles of primary high-grade serous ovarian cancer tumours (N=357) to delineate mecha

177 l siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from

178 , patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more cours

179 meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of

180 pian tubes (the site of origin of high-grade serous ovarian cancer), and whether such changes could t

181 ) (CaMKK2) is highly expressed in high-grade serous ovarian cancer, and we investigated its role in A

182 In high-grade serous ovarian cancer, Galgo signatures obtained similar

183 ef protein levels are elevated in late-stage serous ovarian cancer, high Rgnef mRNA levels are associ

184 n patients with platinum-sensitive recurrent serous ovarian cancer, including those with BRCA1 and BR

185 n patients with platinum-sensitive recurrent serous ovarian cancer, maintenance monotherapy with the

186 xceptional case of a patient with high-grade serous ovarian cancer, treated with multiple chemotherap

187 aluated as a diagnostic probe for high-grade serous ovarian cancer, typically diagnosed at late stage

188 development of drug resistance in high-grade serous ovarian cancer, were examined from patient derive

189 electively target BRCA1-deficient high-grade serous ovarian cancer, which is characterized by frequen

190 with platinum-sensitive, relapsed high-grade serous ovarian cancer.

191 m patients with high grade but not low grade serous ovarian cancer.

192 ortance of metastatic hepatic involvement in serous ovarian cancer.

193 gemcitabine in platinum-resistant high-grade serous ovarian cancer.

194 ely monitor the progression and treatment of serous ovarian cancer.

195 th BRCA-mutated platinum-sensitive recurrent serous ovarian cancer.

196 nning and treatment monitoring of high-grade serous ovarian cancer.

197 overall survival in patients with high-grade serous ovarian cancer.

198 efficacy to gemcitabine alone in high-grade serous ovarian cancer.

199 had a weak positive association with risk of serous ovarian cancer.

200 d overcome platinum resistance in high-grade serous ovarian cancer.

201 erformed phylogenetic analysis of high-grade serous ovarian cancers (68 samples from seven patients),

202 ance in ovarian and other cancers.High-grade serous ovarian cancers (HGS-OvCa) frequently develop che

203 k of effective chemotherapies for high-grade serous ovarian cancers (HGS-OvCa) has motivated a search

204 ombination (HR) repair defects in high-grade serous ovarian cancers (HGSOCs).

205 rexpressed in a subset of primary high-grade serous ovarian cancers and cell lines.

206 amplified with PIK3CA in 29.3% of high-grade serous ovarian cancers and its overexpression is signifi

207 High-grade serous ovarian cancers show increased replication stress

208 utational differences between serous and non-serous ovarian cancers, and further distinguish differen

209 ver clonal populations comprising high-grade serous ovarian cancers.

210 hin the CD49e+ CAF compartment in high-grade serous ovarian cancers.

211 High-grade serous ovarian carcinoma (HGSC), the most common subtype

212 osylation in the heterogeneity of high-grade serous ovarian carcinoma (HGSC), we perform mass spectro

213 A key feature of high-grade serous ovarian carcinoma (HGSOC) is frequent amplificati

214 High-grade serous ovarian carcinoma (HGSOC) is the most frequent ty

215 High-grade serous ovarian carcinoma (HGSOC) is the most lethal gyne

216 High-grade serous ovarian carcinoma (HGSOC) is the most lethal gyne

217 The cell-of-origin of high grade serous ovarian carcinoma (HGSOC) remains controversial,

218 ntified transcriptome subtypes of high-grade serous ovarian carcinoma (HGSOC), but their interpretati

219 tations are a defining feature of high-grade serous ovarian carcinoma (HGSOC).

220 High-grade serous ovarian carcinoma commonly arises from fallopian

221 High-grade serous ovarian carcinoma is characterised by TP53 mutati

222 sed in many carcinomas, including high-grade serous ovarian carcinoma, where it contributes to genomi

223 CDK12 is a recurrently mutated gene in serous ovarian carcinoma, whose downregulation is associ

224 loss as an early event in the development of serous ovarian carcinoma.

225 erived and in-house cohorts of patients with serous ovarian carcinoma.

226 ted with CDK12 inactivation in patients with serous ovarian carcinoma.

227 ession predicts poor prognosis in high-grade serous ovarian carcinoma.

228 respectively, for the majority of high-grade serous ovarian carcinomas (HGSOC) provide the necessary

229 nes and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive cancer

230 peritoneal fluid from women with high-grade serous ovarian carcinomas (HGSOCs).

231 Low-grade serous ovarian carcinomas (LGSC) are associated with a p

232 Low-grade serous ovarian carcinomas (LGSOCs) have historically low

233 ere is growing evidence that most high-grade serous ovarian carcinomas likely arise from local dissem

234 follicle structures and developed low-grade serous ovarian carcinomas with 100% penetrance within 18

235 rotein levels were upregulated in high-grade serous ovarian patient tumors, where the FoxM1 signature

236 involvement in cancer from additional 28 non-serous ovarian tumors and compared our results to TCGA o

237 Many cancers, however, including high-grade serous ovarian, oesophageal, and small-cell lung cancer,

238 Higher CXCR6 expression in serous papillary carcinoma tissues suggests its associat

239 r pigment epithelium detachment (fvPED), and serous PED (sPED).

240 m Black individuals had higher SRF, RPE, and serous PED volumes compared with other ethnic groups.

241 The volume of the migrated RPE cluster in serous PED was significantly correlated with the volume

242 noid pigment epithelial detachment (PED) and serous PED with significantly higher frequencies than in

243 th age-related macular degeneration that had serous PED.

244 k choroid and predominantly nonvascularized, serous PEDs with an overlying neurosensory detachment.

245 5); a similar risk estimate was observed for serous/poorly differentiated tumors (n = 176 cases; comp

246 ented with nystagmus and was found to have a serous RD and a tessellated retinal appearance.

247 Bullous serous retinal detachment (RD) with retinal pigment epit

248 Main outcome measures included resolution of serous retinal detachment (SRD) with single PDT, change

249 choroidal lesions, complicated by recurrent serous retinal detachment (SRD).

250 ion, macular involvement, tumor seeding, and serous retinal detachment [RD] >1 quadrant), timing to e

251 All 26 eyes with a serous retinal detachment at baseline resolved, and 88%

252 loped bilateral anterior uveitis and macular serous retinal detachment during nivolumab treatment for

253 Serous retinal detachment has been described as a rare c

254 apilledema and macular edema associated with serous retinal detachment in the left eye.

255 ral anterior uveitis associated with macular serous retinal detachment related to anti-PD-1 treatment

256 Serous retinal detachment was confirmed on optical coher

257 e optic disc, and the presence or absence of serous retinal detachment, orange lipofuscin pigment, dr

258 tinal thickening, cystoid macular edema, and serous retinal detachment.

259 their metastatic cancer, who had evidence of serous retinal detachments confirmed by optical coherenc

260 an Eye and Ear Hospital with acute bilateral serous retinal detachments without anterior chamber infl

261 posits in both eyes, associated with central serous retinal detachments, a pachychoroid and choriocap

262 clinical and morphologic characteristics of serous retinal disturbances in patients taking mitogen-a

263 ystic changes, choroidal neovascularization, serous retinal elevations mimicking retinal folds, incre

264 he retinal pigment epithelium (RPE) layer in serous retinal pigment epithelium detachment (PED) with

265 tion of human laminin was enhanced following serous seeding.

266 and/or protein expression in all 3 available serous/serous-like BRCA1+ tumors.

267 r after RRSO was not increased, the risk for serous/serous-like endometrial carcinoma was increased i

268 Five serous and/or serous-like (serous/serous-like) endometrial carcinomas were observed

269 CM niche modulated cellular morphology, with serous side seeding resulting in a more rounded aspect r

270 Additionally, serous side seeding significantly increased hMSC adhesio

271 Basement membrane structures on the serous side stimulated hMSC cell monolayer formation, wh

272 iferation was significantly increased on the serous side.

273 compared to normal tissues, including in the serous subtype (p < 0.0001).

274 etion occurs predominantly in poor prognosis serous subtype tumours, and this genetic deletion is ass

275 serous epithelial ovarian cancer, other non-serous subtypes of the disease have not been explored as

276 ncers, and further distinguish different non-serous subtypes.

277 pGs accurately discriminate HGSEMCs from non-serous subtypes.

278 t-associated lymphoid clusters, in mice, the serous surface of the mesenteric adipose streaks contain

279 Serous tubal intra-epithelial carcinoma (STIC) lesions a

280 ation and Tp53 mutation in Pax8 + FTE caused Serous Tubal Intraepithelial Carcinoma (STIC), which met

281 iple concurrent precursor lesions, including serous tubal intraepithelial carcinoma (STIC), with gene

282 the Fallopian tube, which first develops as serous tubal intraepithelial carcinoma (STIC).

283 ssed in early fallopian tube lesions, called serous tubal intraepithelial carcinoma.

284 ting the fallopian tube epithelium (FTE) and serous tubal intraepithelial carcinomas (STIC) as the ti

285 s from early p53 signatures to latter-stage, serous tubal intraepithelial carcinomas (STICs) is chara

286 cted fallopian tube lesions (p53 signatures, serous tubal intraepithelial carcinomas (STICs), and fal

287 d histone H2B monoubiquitylation (H2Bub1) in serous tumorigenesis and report that heterozygous loss o

288 nonsignificantly increased risk of low-grade serous tumors (pOR = 1.48, 95% CI: 0.92, 2.38) was noted

289 erved between androstenedione and high grade serous tumors [ORlog2 = 0.76 (0.60-0.96)].

290 The TAG association with risk overall and serous tumors differed by acyl carbon content and satura

291 m immunohistochemical analyses in 31 uterine serous tumors for ETV6 and 45 basal breast tumors for MI

292 -grade primary tumor patients with papillary serous tumors of the ovary.

293 tumors (3), low grade (4) and high grade (5) serous tumors, and endometrioid tumors (6).

294 iltrating lymphocytes (TILs) from high-grade serous tumors, defined their suppressive capacity in vit

295 nt loss of PAX2 in benign lesions as well as serous tumors.

296 arcinomas, comprising 83 endometrioid and 12 serous tumors.

297 were observed when restricted to high-grade serous tumors.

298 ephritis are not vascularized, but rather of serous type.

299 FBXW7, and KRAS, similar to endometrioid and serous uterine carcinomas.

300 Prevalence of TP53 mutations in non-serous was much lower than in serous epithelial OC, wher